NCT03131934View on ClinicalTrials.gov

Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

May 15, 2025

Conditions
Post-transplant Lymphoproliferative DiseaseTransplant-Related Hematologic Malignancy
Interventions
BIOLOGICAL

Autologous EBV-CTL transduced with vector SFG-CNA12

Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus

BIOLOGICAL

Autologous EBV-CTL transduced with control vector SFG-CNA8

Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8

PROCEDURE

Leucapheresis

Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs

Trial Locations (2)

Unknown

Great Ormond Street Hospital, London

King's College Hospital, London

Sponsors
All Listed Sponsors
collaborator

Genetix Biotherapeutics Inc.

INDUSTRY

lead

University College, London

OTHER

NCT03131934 - Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant | Biotech Hunter | Biotech Hunter